South Pasadena

Researchers are evaluating the effect of tozorakimab, added to standard care, in adults hospitalized with viral lung infection who need supplemental oxygen. The study focuses on preventing death or progression to invasive mechanical ventilation or extracorporeal membrane oxygenation by day 28. This is a Phase III, multicenter, randomized, double-blind trial comparing tozorakimab to placebo in patients with viral lung infection causing acute respiratory failure. Participants will receive a single intravenous dose of either tozorakimab or a matching placebo on the first day of the study. Both groups continue to receive standard care for their viral lung infection. The study is designed to assess the safety and efficacy of tozorakimab as an add-on therapy in this patient population. Throughout the study, researchers will monitor participants for survival and the need for invasive mechanical ventilation or ECMO up to 28 days after treatment. The main outcome measured is the proportion of patients who die or require mechanical ventilation or ECMO by day 28. Participants will be closely observed during hospitalization, with data collected on their respiratory status and treatment outcomes to evaluate the study drug's impact and safety.

Researchers are evaluating the effectiveness and safety of His or Left bundle branch pacing compared to standard biventricular pacing in patients with heart failure caused by left ventricular systolic dysfunction and a left ventricular ejection fraction (LVEF) of 50% or less. The study focuses on patients with either a wide QRS duration of 130 milliseconds or more, or those with anticipated or current right ventricular pacing exceeding 40%, all of whom are receiving standard heart failure medications. The goal is to assess patient-centered outcomes like quality of life, physical activity, heart failure hospitalizations, and mortality, while also monitoring device-related complications and re-interventions.